Several analysts have recently updated their ratings and price targets for Endo International PLC (NASDAQ: ENDP):

  • 10/11/2017 – Endo International PLC was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $9.75 price target on the stock. According to Zacks, “Endo’s top line should continue to benefit from robust performance of Xiaflex and sterile injectables. Endo has centralized and streamlined its supply chain, quality and compliance organization in order to create a more cohesive and efficient structure. The company plans to close its Huntsville, Alabama manufacturing and distribution facilities over the next 12 to 18 months due to declining volumes of commoditized products that affected the Huntsville location. The company expects to transfer majority of the products to other sites while discontinuing approximately 15 products starting in the fourth quarter of 2017 and continuing through 2018. This restructuring is intended to better match manufacturing capacity to projected future demand. However, headwinds in the form of declining generics base business and the legacy branded pain franchise remain. Shares have significantly underperformed the industry so far in 2017.”
  • 10/2/2017 – Endo International PLC was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 9/28/2017 – Endo International PLC is now covered by analysts at Goldman Sachs Group, Inc. (The). They set a “sell” rating and a $7.00 price target on the stock.
  • 9/25/2017 – Endo International PLC was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Endo’s growth-by-acquisition strategy is impressive. Endo’s top line should continue to benefit from robust performance of Xiaflex and sterile injectables. Endo has centralized and streamlined its supply chain, quality and compliance organization in order to create a more cohesive and efficient structure. However, Endo’s generics base business and the legacy branded pain franchise are expected to decline further. The company’s Generic segment is under pressure given the challenging competitive landscape and pricing pressures. With the company pulling off Opana ER from the market over growing concern of opioid abuse epidemic, the top-line will be further impacted. Also, the Branded segment continues to be under pressure due to additional competitive entrants as well as a continuous rise in the number of public policy and regulatory actions. Shares of Endo have significantly underperformed the industry so far.”
  • 9/17/2017 – Endo International PLC had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $9.00 price target on the stock.
  • 9/12/2017 – Endo International PLC had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $14.00 price target on the stock, down previously from $19.00.
  • 9/1/2017 – Endo International PLC was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/18/2017 – Endo International PLC was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 8/14/2017 – Endo International PLC was given a new $10.00 price target on by analysts at Canaccord Genuity. They now have a “hold” rating on the stock.

Endo International PLC (ENDP) opened at 8.98 on Thursday. The company has a 50-day moving average of $8.70 and a 200-day moving average of $10.59. Endo International PLC has a 52 week low of $7.41 and a 52 week high of $21.87. The company’s market cap is $2.01 billion.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The business had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. During the same period last year, the business earned $0.86 EPS. The company’s revenue was down 4.9% on a year-over-year basis. On average, equities research analysts predict that Endo International PLC will post $3.52 EPS for the current year.

In other news, CFO Blaise Coleman acquired 6,500 shares of Endo International PLC stock in a transaction dated Tuesday, August 15th. The shares were acquired at an average cost of $7.89 per share, for a total transaction of $51,285.00. Following the acquisition, the chief financial officer now owns 13,729 shares of the company’s stock, valued at $108,321.81. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Terrance J. Coughlin acquired 20,000 shares of Endo International PLC stock in a transaction dated Thursday, August 10th. The stock was purchased at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the acquisition, the chief operating officer now directly owns 181,369 shares in the company, valued at approximately $1,396,541.30. The disclosure for this purchase can be found here. Insiders bought a total of 36,000 shares of company stock worth $279,460 over the last 90 days. Company insiders own 0.50% of the company’s stock.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.